Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
about
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerA phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.Second-line therapy for esophageal cancer.New and emerging combination therapies for esophageal cancer.Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot studyCombined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.Esophageal cancer chemotherapy: recent advances.Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy.
P2860
Q33377361-120D317B-332A-40B2-B569-34E5DDFB93ACQ33410891-E9329DF7-DAD3-4309-BB51-270921B0B9DEQ33413448-4B7FD876-32F3-4AE1-B50D-B0AE7AE27438Q33426732-138C52E3-ED49-4745-A863-3FC219857A08Q33658659-A90AB376-DD39-4029-88DB-74740A3D618DQ34010159-1BC7D788-5B03-479E-B270-4A508ABB8022Q34543795-66A760F7-332F-48A2-9040-F45CCA2E51DFQ35208094-C84BB311-A423-4859-8DD9-CD0CCD96A52CQ36609800-172CC403-F70C-47E9-BEB8-6644254870F8Q36614602-F22E72D6-C4EA-4CC5-A719-2D8B31FA6152Q36691859-6A2CB911-2FE9-4674-9E47-C0E658BC0C72Q36842786-A0FF05E1-14F7-470B-8E9D-0FF4A6FACC32Q36996728-2336479B-FD4B-4DCD-AAE5-57C78D7714A1Q37116834-E0BB85AC-6430-4B75-B136-26C8997DFE75Q37122423-93C85A99-11A0-4B1C-B310-942E091A565AQ37321790-88F06A5B-AC81-42FC-BEFD-FF027E463F68Q37687535-998D2BAD-9A2E-48CA-9FAE-479E6EC8A88DQ37732285-8BE5A3C1-9BFB-4F66-9622-44D6D4C51650Q38542060-86945CF1-22D4-4539-BB36-964CCD052C35Q40282337-006B748B-54F8-474C-9F31-9E0120E12326Q43194164-895E10E0-A677-4CDD-A18E-5ECDF325321CQ46327752-C83413BE-CA92-45FF-AF84-0F7934337189Q49657442-25B4F84D-A553-4A00-87C6-DCCD19CB7471Q53259440-51078FE8-56F0-4176-B409-0A563BBED7F8
P2860
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@ast
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@en
type
label
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@ast
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@en
prefLabel
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@ast
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@en
P2093
P2860
P356
P1476
Capecitabine plus docetaxel ev ...... l results of a phase II trial.
@en
P2093
R Bredenkamp
S Lorenzen
S von Delius
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602645
P407
P577
2005-06-01T00:00:00Z